Ella Fitszimmons
Sep 10, 2008

Xian Janssen shifts two brands to Bates141

BEIJING - Bates141 has secured the creative duties for two of Johnson & Johnson subsidiary Xian Janssen Pharmaceutical's over-the-counter products, following a pitch contested by two other agencies.

Xian Janssen shifts two brands to Bates141
DMG was the incumbent for Motilium, which has a reported media spend of US$30 million, though it could not be confirmed whether it attempted to defend the account.

Motilium (a stomach motility drug) is currently the most successful OTC medication across categories in China. The second brand, Mylanta, is a new antacid.

Source:
Campaign China

Related Articles

Just Published

2 hours ago

How can AI be leveraged in community engagement?

At IAB's recent event in Hong Kong, panellists from Meta, Netflix, 9Gag, and Xiaohongshu debate the many pros and cons of AI to connect with its communities.

3 hours ago

Is advertising still a viable career for young people?

Campaign explores how an industry reliant on new blood to remain current will need to adapt to appeal to the younger talent it wants.

3 hours ago

The rise of the knowledge athlete

Why creativity not productivity will define the competitive edge, and how professionals are training themselves for an advantage.

4 hours ago

Move and win roundup: Week of September 30, 2024

IPG, The Guardian, Skyscanner and more, in our weekly roundup of people moves and account wins.